Efficacy and Safety of Once‐Weekly Semaglutide 2.0 mg as an Add‐On to Dose‐Reduced Insulin Glargine versus Dose‐Titrated Insulin Glargine in People With Type 2 Diabetes and Overweight (SUSTAIN OPTIMIZE) Authors: Helena W Rodbard, Concetta Irace, Jevitha Lobo, Konstantinos Makrilakis, Prachi Priyadarshini, Suvanjaa Sivalingam, Santiago Tofé Povedano, Anuj Bhargava Published: 2026 ABSTRACT ABSTRACTAimsType 2 diabetes (T2D) management with basal insulin can lead to hypoglycaemia and weight gain. SUSTAIN OPTIMIZE compared once‐weekly semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine (Sema+IGlarreduced) versus dose‐titrated IGlar (IGlartitrated) on glycated haemoglobin (HbA1c), body weight (BW), daily insulin dose, and participant satisfaction.Materials and MethodsSUSTAIN OPTIMIZE was a 40‐week, phase 3b, open‐label, randomised study. Adults with T2D, overweight (body mass index ≥ 25 kg/m2), and treatment with basal insulin ≤ 40 units/day were randomised 1:1 into Sema+IGlarreduced or IGlartitrated. The primary endpoint was change in HbA1c using a non‐inferiority approach. Secondary endpoints assessed superiority of Sema+IGlarreduced versus IGlartitrated in reducing HbA1c, BW, daily insulin dose, and improving Diabetes Treatment Satisfaction Questionnaire change version (DTSQc) scores.ResultsOverall, 573 participants were randomised. Sema+IGlarreduced achieved both non‐inferiority and superiority versus IGlartitrated in HbA1c reduction (estimated treatment difference [ETD]: −0.74%; 95% confidence interval [CI95]: −0.90, −0.59) and superiority in BW change (ETD: −8.5 kg; CI95: −9.5, −7.4), relative daily insulin dose change (ETD: −121.9%; CI95: −143.1, −100.6), and DTSQc scores (ETD: 2.6; CI95: 1.6, 3.5) (p < 0.0001 for all endpoints). No new safety concerns were identified. Severe hypoglycaemia was reduced (rate ratio: 0.45; CI95: 0.23, 0.87; p = 0.02), while gastrointestinal events were higher for Sema+IGlarreduced (310 vs. 32 events).ConclusionsOnce‐weekly subcutaneous semaglutide 2.0 mg as add‐on to dose‐reduced IGlar achieved superior reductions in HbA1c, BW, and daily insulin dose in people with T2D and overweight, while reducing their risk for severe hypoglycaemia compared to dose‐titrated IGlar alone.Keywords: clinical trial, GLP‐1, glycaemic control, hypoglycaemia, insulin glargine, semaglutide Introduction Type 2 diabetes (T2D) is a disease characterised by decreased pancreatic β‐cell function and increased insulin resistance, which contribute to hyperglycaemic conditions [1]. T2D is progressive in nature, and poor glycaemic control can result in the development of both micro‐ and macrovascular complications [2]. Due to the progressive nature of T2D, treatment regimens must be adapted to the individual to manage glycaemic levels properly [3]. According to the American Diabetes Association and the European Association for the Study of Diabetes (ADA/EASD), weight management and lifestyle interventions remain central to T2D management [4]; however, current recommendations endorse the use of pharmacologic agents in combination with these treatment approaches. Despite the improved approaches in managing T2D, basal insulin, such as insulin glargine (IGlar), is eventually recommended for many people with T2D to reduce glucose levels [5, 6]. However, insulin therapy frequently requires treatment intensification to achieve glycaemic targets [7]. Current guidelines advocate for the use of glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs), such as semaglutide, as a preferred therapeutic over insulin treatment for the management of T2D [5]. In addition to its proven efficacy in reducing glycated haemoglobin (HbA1c) and body weight (BW), semaglutide has been shown to improve cardiovascular (CV) and kidney outcomes in people with T2D and established CV disease or chronic kidney disease [8, 9, 10, 11]. Previous SUSTAIN studies (SUSTAIN 4 and 5) have shown that people with T2D taking once‐weekly (OW) subcutaneous (s.c.) semaglutide have experienced greater glycaemic efficacy than insulin intensification treatment alone, without the associated weight gain or higher frequency of hypoglycaemic episodes that are observed in people on insulin intensification treatment [12, 13]. SUSTAIN 5 provided valuable insight into the effects of semaglutide as an add‐on to basal insulin on glycaemic control, whereby it was found that OW s.c. semaglutide 0.5 and 1.0 mg doses were both superior to placebo in reducing HbA1c and BW [12]. Moreover, the SUSTAIN FORTE trial investigated the intensification of OW s.c. semaglutide treatment (2.0 vs. 1.0 mg) in people with T2D, wherein OW s.c. semaglutide 2.0 mg was superior to 1.0 mg in reducing HbA1c and BW [14]. The SUSTAIN 5 and SUSTAIN FORTE studies highlight the limitations of basal insulin–centred intensification strategies and a dose‐dependent effect, with the 2.0 mg semaglutide dose providing superior efficacy versus 1.0 mg. In this context, we aimed to investigate the efficacy and safety of OW s.c. semaglutide 2.0 mg as an add‐on to dose‐reduced IGlar U100 (Sema+IGlarreduced) versus dose‐titrated IGlar U100 without semaglutide (IGlartitrated) in people with T2D and overweight, suggesting that it would be a more efficacious and safer alternative for achieving glycaemic control with a lower risk of weight gain and hypoglycaemia. Materials and Methods Study Design and Participants SUSTAIN OPTIMIZE (NCT05514535) was a 40‐week, phase 3b, open‐label, parallel‐group, randomised trial performed at 113 outpatient clinical trial sites in 9 countries across North America (USA), Europe (Czech Republic, Greece, Italy, Portugal, Romania, Slovakia, Spain), and Africa (South Africa). The trial was conducted in compliance with the International Conference on Harmonisation Good Clinical Practice guidelines and the Declaration of Helsinki. All participants provided written informed consent before the trial commenced. This trial is registered with ClinicalTrials.gov, NCT05514535, and is completed. Participants were eligible for the study if the following criteria were met: aged ≥ 18 years, having T2D ≥ 180 days before screening, HbA1c level of 7%–10% (53–86 mmol/mol) (both inclusive), body mass index (BMI) ≥ 25 kg/m2, treatment with a once‐daily basal insulin ≤ 40 units/day for at least 90 days before screening, and on a stable dose of metformin (≥ 1500 mg or maximum tolerated or effective dose) with or without sodium‐glucose cotransporter‐2 inhibitors (SGLT2is) for at least 90 days before screening. Key exclusion criteria included the presence of uncontrolled retinopathy or maculopathy (verified by a fundus examination performed within 90 days before screening or in the period between screening and randomisation), potential missed diagnosis of type 1 diabetes (verified by C‐peptide < 0.26 nmol/L or antibodies to glutamic acid decarboxylase > 5 units/mL), presence or history of pancreatitis (acute or chronic), renal impairment (estimated Glomerular Filtration Rate < 30 mL/min/1.73 m2), and known hypoglycaemic unawareness as indicated by the investigator according to Clarke's questionnaire question 8. Additionally, participants on sulfonylureas were excluded from the study. Randomisation and Masking Participants were randomised in a 1:1 ratio to receive Sema+IGlarreduced or IGlartitrated. Randomisation was stratified based on background treatment with SGLT2is. The open‐label design was applied due to the different approaches to insulin titration in the two arms. IGlar U100 was chosen as the once‐daily basal insulin because it is a well‐established comparator that has been extensively evaluated. Furthermore, titration of IGlar U100 was expected to result in at least 0.5%‐points improvement in HbA1c, justifying the smaller margin of 0.3%‐point specified below (see Outcomes) as the threshold for the primary objective in this study [15, 16, 17]. Procedures The study consisted of a 2‐week screening period followed by a 40‐week intervention period and a subsequent 5‐week follow‐up period. The semaglutide treatment arm underwent a 12‐week dose escalation period where participants were initiated on a OW dose of 0.25 mg, followed by a fixed‐dose escalation regimen that increased every 4 weeks (to 0.5, 1.0, and 2.0 mg/week) until the target maintenance dose of 2.0 mg was reached after 12 weeks. Semaglutide dose escalation was carried out simultaneously with IGlar dose de‐escalation; participants followed a fixed‐dose de‐escalation regimen that reduced the dose of IGlar by 10 U every 4 weeks, according to Table S1. Both arms underwent insulin titration according to a fixed insulin titration plan, which adjusted IGlar doses according to pre‐breakfast self‐measured blood glucose (SMBG) values obtained on the day of titration and on the 2 days prior to titration, according to Table S2. All participants were provided with a standardised SMBG meter and an electronic diary to record their blood glucose values. Insulin titration was performed from baseline to week 40 for both arms. For the semaglutide treatment arm, participants received SMBG‐guided titration during the first 12 weeks (which was consistent with the dose‐titrated comparator) while simultaneously undergoing IGlar de‐escalation, followed by titration‐only from week 12 to end of trial (EoT). Outcomes The primary endpoint was change in HbA1c (%‐points) from baseline to week 40, tested for non‐inferiority of Sema+IGlarreduced compared to IGlartitrated, where a predetermined non‐inferiority margin of 0.3%‐points for HbA1c treatment difference was judged as being a clinically acceptable loss of efficacy compared to IGlartitrated in the context of expected benefits. Confirmatory secondary endpoints (tested hierarchically upon success of the primary endpoint) were change in BW (kg), relative change in daily insulin dose (%), change in HbA1c (for superiority), and change in score for the Diabetes Treatment Satisfaction Questionnaire (DTSQc) at EoT. All confirmatory secondary endpoints were tested for superiority, with the null hypothesis of no difference between treatment groups (two‐sided α = 0.05). Key supportive secondary endpoints included an assessment of the number of participants achieving an insulin dose of 0 U at EoT, an insulin dose reduction from baseline by at least 50% at EoT, and an HbA1c < 7% at EoT. The number of severe hypoglycaemic episodes (level 3 [presence of neuroglycopenic symptoms and the necessity of external assistance to treat low blood glucose]), clinically significant hypoglycaemic episodes (level 2 [< 3.0 mmol/L (54 mg/dL) confirmed by SMBG metre]), and a combination of the number of either level 2 or level 3 episodes were also part of the supportive secondary endpoints. Post‐hoc exploratory analyses included the number of participants with HbA1c < 6.5%, relative BW change (%), proportion of participants achieving progressively higher categories of relative BW loss (≥ 5/≥ 10/≥ 15/≥ 20%), absolute change in daily insulin dose from baseline to EoT (U/day), a combined target of HbA1c < 6.5% and weight‐loss of ≥ 5% and ≥ 10%, and the number of participants with ≤ 10 U insulin/day at EoT. Additional post hoc analyses included composite endpoints for identifying the number of participants that reached an HbA1c < 7% with no hypoglycaemic episodes and no weight gain, the number of participants that reached an HbA1c < 7% with no hypoglycaemic episodes, and the number of participants that reached an HbA1c < 6.5% with no hypoglycaemic episodes. Statistical Analysis The trial was designed with a target enrolment of 568 participants, randomly assigned in a 1:1 ratio to receive Sema+IGlarreduced versus IGlartitrated. The study was primarily designed to demonstrate non‐inferiority of Sema+IGlarreduced versus IGlartitrated for change from baseline in HbA1c at week 40, but it aimed to achieve at least 90% statistical power to demonstrate the superiority of Sema+IGlarreduced versus IGlartitrated in terms of change from baseline in HbA1c at week 40. The power was calculated using a one‐sided t‐test with a significance level of 0.025, with an anticipated treatment difference of −0.3%‐points and a standard deviation of 1.1%‐points. With 568 participants, a power of > 99.9% for confirming a non‐inferior effect (with a non‐inferiority margin of 0.3%‐points) on change from baseline to week 40 in HbA1c (%‐point) of Sema+IGlarreduced versus IGlartitrated, was obtained. A hierarchical testing strategy was implemented to control the overall two‐sided type I error rate at an α level of 0.05 across the confirmatory endpoints: (1) Change from baseline to week 40 in HbA1c (%‐point) non‐inferiority of Sema+IGlarreduced versus IGlartitrated; superiority of Sema+IGlarreduced versus IGlartitrated in (2) Change from baseline to week 40 in BW (kg), (3) Relative change from baseline to week 40 in daily insulin dose (%), (4) Change from baseline to week 40 in HbA1c (%‐point), and (5) DTSQc score at week 40. Efficacy endpoints were analysed in the full analysis set, which included all randomly assigned participants exposed to at least one dose of the study drug during the treatment period irrespective of premature treatment discontinuation and/or change in background medication. Safety endpoints were summarised descriptively and analysed in the safety population, comprising all participants who received at least one dose of trial treatment, analysed as treated. Primary and confirmatory secondary endpoints were evaluated under two estimands: the treatment regimen estimand and the efficacy estimand. Unless otherwise specified, the treatment regimen estimand was applied to other secondary and exploratory endpoints. Safety analyses were based on all randomised participants who received at least one dose of the study drug, with data included from treatment initiation through the end of the safety follow‐up period. The treatment regimen estimand evaluated treatment effect in all randomly assigned participants based on the in‐trial observation period, regardless of treatment discontinuation or initiation of rescue treatment irrespective of premature treatment discontinuation and/or change in background medication. Missing EoT data were imputed using multiple imputation (MI) assuming that missing data were missing at random (MAR). The imputation was performed by imputing missing EoT data separately within groups defined by randomised treatment and treatment status at EoT. For continuous endpoints, an analysis of covariance (ANCOVA) model with randomised treatment, SGLT2i use (Y/N) and region as factors and baseline response as a covariate was used to obtain the estimated treatment difference (ETD) along with the two‐sided 95% confidence intervals (CIs) and p values. Tipping‐point analyses were conducted to assess the robustness of the superiority conclusions to different assumptions regarding missing data. For categorical endpoints, logistic regression with the same fixed effects and covariate as continuous endpoints was used to obtain the estimated odds ratio along with the two‐sided 95% CIs and p values. The efficacy estimand evaluated treatment effect in all randomly assigned participants based on the on‐treatment observation period irrespective of change in background medication. Missing EoT data were imputed using MI assuming that missing data were MAR. For each group, an ANCOVA with SGLT2i use (Y/N) and region as factors and baseline HbA1c as a covariate was fitted to the observed EoT values. The estimated location and dispersion parameters were then used to impute 500 values for each participant with missing EoT data. The seed for imputation was set to 22071430. The software used for analyses was SAS software. Results Baseline Characteristics This study was conducted between August 29, 2022, and April 09, 2025. In this study, 573 participants were randomly assigned to treatment in both arms, which made up the full analysis set. Of these, 288 participants were exposed to Sema+IGlarreduced, 284 were exposed to IGlartitrated, and 1 participant was not exposed to treatment. Overall, 283 participants completed the trial for the Sema+IGlarreduced arm, while 275 completed the trial for the dose‐titrated IGlartitrated arm (Figure S1). Baseline characteristics were balanced across the treatment groups. Overall, participants had a mean age of 61.1 years, mean HbA1c of 7.9% (63.2 mmol/mol), mean BW of 93.9 kg, mean BMI of 33.0 kg/m2, mean duration of diabetes of 12.4 years, median IGlar dose of 27.0 U, and 48% of participants were using SGLT2is at baseline (Table 1). TABLE 1Baseline Characteristics.Sema + IGlarreduced (n = 288)IGlartitrated (n = 285)Overall (n = 573)Age, years61.7 (9.7)60.5 (10.3)61.1 (10.0)Sex, n (%)Female124 (43.1%)129 (45.3%)253 (44.2%)Male164 (56.9%)156 (54.7%)320 (55.8%)Region, n (%)Africa35 (12.2%)25 (8.8%)60 (10.5%)Europe196 (68.1%)205 (71.9%)401 (70.0%)North America57 (19.8%)55 (19.3%)112 (19.5%)Race, n (%)Asian33 (11.5%)22 (7.7%)55 (9.6%)Black or African American10 (3.5%)9 (3.2%)19 (3.3%)Native Hawaiian or Other Pacific Islander1 (0.3%)01 (0.2%)White243 (84.4%)253 (88.8%)496 (86.6%)Multiple1 (0.3%)01 (0.2%)Ethnicity, n (%)Hispanic or Latino27 (9.4%)31 (10.9%)58 (10.1%)Not Hispanic or Latino261 (90.6%)254 (89.1%)515 (89.9%)Duration of type 2 diabetes, years12.4 (7.7)12.4 (7.4)12.4 (7.5)Body weight, kg92.6 (17.9)95.2 (20.6)93.9 (19.3)BMI, kg/m2 32.5 (5.3)33.4 (5.9)33.0 (5.6)BMI, kg/m2, n (%)≤ 30106 (36.8%)93 (32.6%)199 (34.7%)> 30182 (63.2%)191 (67.0%)373 (65.1%)Systolic blood pressure, mmHg132 (14)133 (14)132 (14)Diastolic blood pressure, mmHg78 (9)79 (9)79 (9)HbA1c, %7.9 (0.7)7.9 (0.6)7.9 (0.7)HbA1c, mmol/mol63.0 (7.3)63.3 (7.1)63.2 (7.2)Total daily dose of IGlar, U, median26.028.027.0Fasting plasma glucose, mmol/L8.5 (2.5)8.5 (2.5)8.5 (2.5)eGFR, mL/min/1.73 m2, geometric mean (CV)86.8 (24.5)88.1 (22.9)87.4 (23.7)Total cholesterol, mmol/L, geometric mean (CV)4.1 (27.9)4.0 (24.3)4.0 (26.2)LDL cholesterol, mmol/L, geometric mean (CV)2.1 (51.3)2.0 (43.2)2.0 (47.4)HDL cholesterol, mmol/L, geometric mean (CV)1.1 (24.6)1.1 (25.2)1.1 (24.9)Triglycerides, mmol/L, geometric mean (CV)1.7 (54.7)1.7 (56.1)1.7 (55.4)Smoker status, n (%)Current smoker47 (16.3%)45 (15.8%)92 (16.1%)Never smoked169 (58.7%)171 (60.0%)340 (59.3%)Previous smoker72 (25.0%)69 (24.2%)141 (24.6%)SGLT2is, n (%)138 (47.9%)137 (48.1%)275 (48.0%)Abbreviations: BMI, body mass index; CV, coefficient of variation; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; IGlartitrated, dose‐titrated insulin glargine; LDL, low‐density lipoprotein; SD, standard deviation; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGTL2is, sodium‐glucose cotransporter‐2 inhibitors; U, unit. Baseline Characteristics. Abbreviations: BMI, body mass index; CV, coefficient of variation; eGFR, estimated glomerular filtration rate; HbA1c, glycated haemoglobin; HDL, high‐density lipoprotein; IGlartitrated, dose‐titrated insulin glargine; LDL, low‐density lipoprotein; SD, standard deviation; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGTL2is, sodium‐glucose cotransporter‐2 inhibitors; U, unit. Glycaemic Control At EoT, the mean HbA1c was 6.5% (48.0 mmol/mol) for the Sema+IGlarreduced arm and 7.3% (56.0 mmol/mol) for the IGlartitrated arm. From baseline to week 40, the mean change in HbA1c %‐points was −1.4% for the Sema+IGlarreduced arm and −0.6% for the IGlartitrated arm. The ETD for Sema+IGlarreduced versus IGlartitrated was −0.74% (95% CI: −0.90 to −0.59; p < 0.0001 for non‐inferiority) (Figure 1A). Non‐inferiority for Sema+IGlarreduced versus IGlartitrated in HbA1c change was achieved and superiority was confirmed. There was a larger proportion of participants that achieved the predefined HbA1c targets of < 7.0% and the post‐hoc exploratory target of < 6.5% for Sema+IGlarreduced (77.6% and 52.2%, respectively) versus IGlartitrated (39.0% and 14.8%, respectively) at week 40 (Figure 2). Change in HbA1c, body weight, and insulin dose. Mean ± SE are graphed for A–C; ****p < 0.0001. Error bars may not be visible due to low SE values. Sema+IGlarreduced is represented by dark blue, closed circles and IGlartitrated is represented by dark green, closed squares. Panel A shows the change in HbA1c from week 0 to week 40 and the estimated HbA1c change at week 40 between Sema+IGlarreduced vs. IGlartitrated. Panel B shows the change in body weight from week 0 to week 40 and the estimated body weight change at week 40 between Sema+IGlarreduced vs. IGlartitrated. Panel C shows the relative change in daily insulin dose from week 0 to week 40 and the estimated relative change in daily insulin dose at week 40. ETD, estimated treatment difference; HbA1c, glycated haemoglobin; IGlartitrated, dose‐titrated insulin glargine; SD, standard deviation; SE, standard error; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine. Participants achieving HbA1c response criteria at week 40. A. Percentage of participants achieving the predefined efficacy target of HbA1c < 7%; B. Percentage of participants achieving the exploratory efficacy target of HbA1c < 6.5%; C. Table of participants achieving response criteria at week 40 from on‐treatment observed data. Hypoglycaemic episodes constituted as a reading of < 3.9 mmol/L confirmed by blood glucose meter. Data from in‐study with missing continuous endpoint was multiple imputed using observed data from participants within the same group defined by randomised treatment and treatment status at end of treatment that was applicable for respective endpoints. After imputation, data was dichotomised. HbA1c, glycated haemoglobin; IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine. There were 14 (4.9%) participants in the Sema+IGlarreduced arm who experienced clinically significant hypoglycaemia (level 2) compared to 21 (7.4%) participants in the IGlartitrated arm, and 4 (1.4%) participants in the Sema+IGlarreduced arm experienced severe hypoglycaemia (level 3) compared to 11 (3.9%) participants in the IGlartitrated arm (Table 2). The rate of clinically significant (level 2) or severe hypoglycaemia (level 3) was lower with Sema+IGlarreduced versus IGlartitrated (0.08 vs. 0.19 events per 100 patient‐years), corresponding to a rate ratio of 0.45 (95% CI: 0.23–0.87; p = 0.02) (Table S3). TABLE 2Safety outcomes in the safety analysis set.Number of participantsSema + IGlarreduced IGlartitrated 288284Adverse events N (%) E R N (%) E R Total a 17360.1678280.115253.5412171.9Serious175.9249.9155.3218.8Fatal b 10.310.410.410.4SeverityMild13546.9476196.612142.6279116.4Moderate c 7526.017572.36021.111849.2Severe d 134.52711.2113.9156.3OutcomeRecovered15453.5553228.512544.0283118.1Recovering144.9187.4124.2156.3Recovered with sequelae0000Not recovered6121.210041.35619.710945.5Unknown51.762.531.141.7Leading to treatment discontinuation103.5104.110.410.4Gastrointestinal adverse events41.441.70Gastrointestinal adverse eventsOverall10636.8310128.1196.73213.4Recovered9533.0280115.7176.02811.7Recovering72.4104.110.410.4Mild8529.523195.4124.2208.3Moderate4013.96727.7103.5114.6Severe41.4125.010.410.4Nausea5318.49740.120.720.8Vomiting289.74819.810.410.4Diarrhoea3913.55522.7124.2145.8Pancreatitis10.310.40Acute pancreatitis10.310.410.410.4HypoglycaemiaHypoglycaemia alert value (Level 1)4816.711748.39332.7391163.2Clinically significant hypoglycaemia (level 2) e 144.9166.6217.43213.4Severe hypoglycaemia (level 3) f 41.462.5113.9145.8Cardiac adverse events72.483.362.183.3Gallbladder‐related adverse events51.752.120.720.8Neoplasms51.752.131.131.3Diabetic retinopathy51.752.1113.9114.6 Note: Severity relationships are based on investigators' assessment. N: number of participants with at least one event, %: proportion of participants with at least one event, E: number of events, R: events per 100 patient‐years of exposure.Abbreviations: %, percentage of participants experiencing at least one event; E, number of events; GI, gastrointestinal; IGlartitrated, dose‐titrated insulin glargine; N, number of participants experiencing at least one event; R, event rate per 100 exposure years; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SOC, system organ class. a Most common AE by SOC were GI disorders (E = 227 in Sema+IGlarreduced vs. E = 17 in IGlartitrated). b Cause of death: Sema+IGlarreduced: pericarditis; IGlartitrated: acute heart attack. c 1 pancreatitis in Sema+IGlarreduced, 0 in IGlartitrated. d 1 acute pancreatitis in each arm. e Glucose value < 3 mmol/L. f No glucose threshold, requires assistance from another person. Safety outcomes in the safety analysis set. Note: Severity relationships are based on investigators' assessment. N: number of participants with at least one event, %: proportion of participants with at least one event, E: number of events, R: events per 100 patient‐years of exposure. Abbreviations: %, percentage of participants experiencing at least one event; E, number of events; GI, gastrointestinal; IGlartitrated, dose‐titrated insulin glargine; N, number of participants experiencing at least one event; R, event rate per 100 exposure years; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SOC, system organ class. Most common AE by SOC were GI disorders (E = 227 in Sema+IGlarreduced vs. E = 17 in IGlartitrated). Cause of death: Sema+IGlarreduced: pericarditis; IGlartitrated: acute heart attack. 1 pancreatitis in Sema+IGlarreduced, 0 in IGlartitrated. 1 acute pancreatitis in each arm. Glucose value < 3 mmol/L. No glucose threshold, requires assistance from another person. Change in Body Weight At EoT, the mean BW was 84.6 kg for the Sema+IGlarreduced arm and 95.2 kg for the IGlartitrated arm. From baseline, the mean change in BW (kg) at week 40 was −8.0 kg for the Sema+IGlarreduced arm and + 0.5 kg for the IGlartitrated arm. The ETD for Sema+IGlarreduced versus IGlartitrated was −8.5 kg (95% CI: −9.5 to −7.4; p < 0.0001 for superiority) (Figure 1B). For the post‐hoc exploratory analysis regarding the relative change in BW (%) at week 40, the ETD was −9.3% (95% CI: −10.4 to −8.2) (Figure S2). In this analysis, 73.2% of participants demonstrated BW reduction ≥ 5% in the Sema+IGlarreduced arm versus 9.1% in the IGlartitrated arm, while 38.0% of participants in the Sema+IGlarreduced arm achieved ≥ 10% BW reduction compared to 1.6% in the IGlartitrated arm (Figure 3). In an analysis of composite endpoints, 43.6% of participants receiving Sema+IGlarreduced achieved both HbA1c < 6.5% and BW reduction ≥ 5% versus 3.4% of participants receiving IGlartitrated (Figure S3). For the stricter exploratory composite endpoint (HbA1c < 6.5% and ≥ 10% BW reduction), the corresponding proportions were 23.9% versus 0.5% (Figure S3). Proportion of participants achieving exploratory weight reduction thresholds. Exploratory efficacy endpoints are graphed for A–D, representing the proportion of participants achieving ≥ 5%, ≥ 10%, ≥ 15%, and ≥ 20% weight reduction, respectively. Data from in‐study with missing body weight were multiple‐imputed using observed data from participants within the same group defined by randomised treatment and same treatment status. After imputation, continuous data were dichotomised. IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine. Relative Change in Insulin Dose From baseline, the mean relative change in insulin dose (%) at week 40 was −17.8% for the Sema+IGlarreduced arm and + 104.1% for the IGlartitrated arm. The ETD for Sema+IGlarreduced versus IGlartitrated was −121.9% (95% CI: −143.1 to −100.6; p < 0.0001 for superiority) (Figure 1C). According to the post‐hoc exploratory analysis for daily insulin dose at EoT, the absolute change in daily insulin dose at week 40 was −5.2 U/day for the Sema+IGlarreduced arm and + 20.1 U/day for the IGlartitrated arm (ETD: −25.3 U/day; 95% CI: −28.8 to −21.7; p < 0.0001 for superiority) (Figure S4). For predefined endpoints, the proportion of participants achieving insulin dose targets was 12.9% of participants on Sema+IGlarreduced who achieved an insulin dose of 0 U at 40 weeks compared to 0.1% of participants receiving IGlartitrated, while 35.6% of participants in the Sema+IGlarreduced arm achieved ≥ 50% insulin dose reduction at week 40 versus 0.7% in the IGlartitrated arm. For the exploratory post‐hoc analyses, 32.1% of the Sema+IGlarreduced arm achieved ≤ 10 U at week 40 versus 1.4% of the IGlartitrated arm (Figure S5). Treatment Satisfaction For participant treatment satisfaction (measured by DTSQc score) at week 40, the mean score for Sema+IGlarreduced was 14.6 compared to 12.1 for IGlartitrated. The ETD for Sema+IGlarreduced versus IGlartitrated was 2.6 (95% CI: 1.6 to 3.5; p < 0.0001 for superiority) (Figure S6). Safety The number of participants experiencing adverse events (AEs) was 173 (60.1%) in the Sema+IGlarreduced arm compared to 152 (53.5%) in the IGlartitrated arm (Table 2). The most common AE was gastrointestinal (GI) disorders (106 participants experiencing events for Sema+IGlarreduced vs. 19 participants for IGlartitrated). However, 95 versus 17 participants recovered and 7 versus 1 participant were recovering from GI AEs by EoT for Sema+IGlarreduced versus IGlartitrated, respectively. The number of participants experiencing serious adverse events was 17 (5.9%) participants in the Sema+IGlarreduced arm compared to 15 (5.3%) participants in the IGlartitrated arm (Table 2). There were 10 (3.5%) participants in the Sema+IGlarreduced arm who discontinued treatment due to AEs compared to 1 (0.4%) participant in the IGlartitrated arm who stopped due to a suspected malignant neoplasm (unlikely related to IGlar treatment). Discussion In the SUSTAIN OPTIMIZE study, we demonstrated a non‐inferiority for Sema+IGlarreduced compared to IGlartitrated on HbA1c reduction (primary estimand), as well as a superiority for Sema+IGlarreduced over IGlartitrated in reducing HbA1c, BW, and the daily basal insulin dose used by participants, while also reducing the risk of severe hypoglycaemic episodes and improving participant treatment satisfaction. The reduction in HbA1c is consistent with the results observed in previous SUSTAIN trials and the reduction in BW is the largest observed in the entire SUSTAIN program [12, 18, 19, 20], which supports the robust nature of semaglutide. SUSTAIN 5 investigated semaglutide as add‐on to basal insulin, where HbA1c reductions were −1.4% and −1.8% for 0.5 and 1.0 mg semaglutide, and BW reductions were −3.7 and −6.4 kg for 0.5 and 1.0 mg semaglutide, respectively [12]. Compared to participants receiving IGlartitrated, a significantly greater proportion of those in the Sema+IGlarreduced arm achieved key glycaemic targets, including HbA1c < 7.0% and the more stringent HbA1c < 6.5% target. The proportion of participants in this study that achieved HbA1c < 7.0% is consistent with findings across the entire SUSTAIN program [12, 18, 19, 20, 21, 22]. Furthermore, a higher percentage of participants treated with semaglutide also reached the combined endpoints of HbA1c < 6.5% and clinically meaningful BW reductions of ≥ 5% and ≥ 10%. The findings are especially promising in a population where hypoglycaemia and weight gain often limit optimal basal insulin titration and glycaemic control. The benefits of semaglutide as add‐on treatment are further reflected in participant treatment satisfaction, which was measured by DTSQc scores. Compared to IGlartitrated treatment, Sema+IGlarreduced was associated with improvements in treatment satisfaction. The treatment effect for DTSQc score at week 40 for Sema+IGlarreduced is comparable to previous GLP‐1 RA studies [23], and was higher than the scores observed in previous SUSTAIN trials [12, 13, 19, 21, 22]. While participants might have been influenced in their evaluation of the treatment due to the nature of the open‐label design, the increased treatment satisfaction associated with semaglutide treatment is expected to be beneficial in people with T2D as it relates to the high treatment burden and related compliance issues associated with all forms of insulin therapy [24]. To account for this high treatment burden and associated compliance issues, we investigated the daily insulin use at EoT. We found that Sema+IGlarreduced treatment not only decreased daily insulin use, but also significantly reduced the occurrence of severe hypoglycaemia compared to IGlartitrated treatment. However, the population size was not powered for comparison of hypoglycaemia between arms, so these results should be interpreted with caution. Furthermore, a large proportion of participants in the Sema+IGlarreduced arm was using < 10 U/day of IGlar at EoT, which is a negligible amount of insulin that can potentially be de‐escalated in most cases. Compared to SUSTAIN 5, which showed a −10% and −15% reduction in daily insulin dose for semaglutide 0.5 and 1.0 mg, respectively, we found a daily dose reduction of −17.8% for semaglutide 2.0 mg, which may indicate that a higher dose of semaglutide use could benefit in reducing daily insulin use [12]. In the IGlartitrated comparator arm, basal insulin was intensified based on rigorous SMBG‐guided titration to a fasting glucose target (i.e., treat‐to‐target), ensuring robust insulin up‐titration without arbitrary dose increases. Conversely, in the Sema+IGlarreduced arm, IGlar was proactively reduced by 10 U at each 4‐week semaglutide dose escalation step (to minimise hypoglycaemia), after which standard SMBG‐based IGlar titration was resumed. These protocol‐driven strategies—while necessary for safety and rigour—may limit direct generalisability to routine practice. Semaglutide was well tolerated, and the AE profile was similar to that of other GLP‐1 RAs [25]. As expected, there were more GI AEs in the Sema+IGlarreduced arm compared to the IGlartitrated arm, while the majority of GI AEs in the semaglutide arm were not severe in nature and led to treatment discontinuation in 4 participants. Overall, no new safety concerns were identified from this study. Therefore, OW s.c. semaglutide 2.0 mg as add‐on to dose‐reduced IGlar provides a safe treatment alternative to basal insulin titration alone. There were some limitations to the SUSTAIN OPTIMIZE trial. The open‐label design of this trial was one limitation, which was implemented due to the different approaches to titration in the two arms. This open‐label design could have an impact on the participant satisfaction scores, as measured by DTSQc, and the scores should therefore be interpreted in the context of this open‐label design. Secondly, the results presented in this study may be limited in their general applicability to a wider population. Since this study included only participants on ≤ 40 U/day and with baseline HbA1c levels between 7%–10%, we did not determine the effect of intervention on those with > 40 U/day or on participants presenting with HbA1c > 10%. Additionally, the baseline characteristics favoured a large proportion of White participants and participants from Europe. However, a post‐hoc analysis focusing on the impact of race/ethnicity has previously been performed on the SUSTAIN trials, which found that semaglutide was associated with consistent and clinically relevant reductions in HbA1c and BW in participants with T2D, with minor variations in efficacy and safety outcomes associated with race/ethnicity [26]. Thirdly, there was an apparent decline in participant numbers in both study arms for the daily insulin dose endpoint, most notably in the semaglutide arm at week 40. However, this can be explained by the fact that semaglutide doses were increased and IGlar use was reduced by 10 U with each up‐titration to prevent hypoglycaemia. Consequently, several participants in the semaglutide group reached 0 U insulin; however, those zero values were not documented correctly and were recorded as missing. Among the 288 participants in the Sema+IGlarreduced arm, 106 had missing data following imputation and were not directly imputed to zero because no confirmatory evidence was available. The data for these participants were imputed assuming MAR. Tipping point analysis as sensitivity analysis was conducted to look for the robustness of the result. Importantly, however, this issue does not alter our study's conclusions. In fact, had those zeros been included, the treatment difference in insulin use would likely be even larger in favour of the Sema+IGlarreduced arm. Another limitation was that patient‐reported outcomes at EoT were not collected on time; a few were documented only after the study ended and thus were not eligible to be considered for EoT visit. The data for these subjects were therefore treated as missing. Despite this limitation, overall treatment satisfaction was significantly better in the Sema+IGlarreduced arm compared to the IGlartitrated arm. Due to the nature of using DTSQc scores as a measurement tool, we were not able to capture baseline satisfaction among participants. However, participants were randomised into each arm, so baseline satisfaction should have been similar. Still, DTSQc scores were deliberately chosen to focus on change, so there may be some uncertainty in this conclusion. Compared to SUSTAIN FORTE, there was a lower reduction in HbA1c levels observed in this study [14]. This may be explained by the higher baseline HbA1c in SUSTAIN FORTE, which likely contributed to the greater reduction observed in that study. Finally, the fixed insulin titration and de‐escalation protocol used in this study may not reflect certain routine clinical practice and may influence the generalisability of the results presented here. In many clinical settings, however, the next step after inadequate control on basal insulin plus oral agents is adding prandial insulin rather than further up‐titrating basal insulin. In SUSTAIN 11, that approach was indeed tested by comparing OW semaglutide to a basal‐bolus regimen with insulin in people with T2D already taking basal insulin and metformin [27]. In contrast, SUSTAIN OPTIMIZE was designed to evaluate whether optimising OW semaglutide 2.0 mg in people with T2D and overweight, who were already on basal insulin plus metformin (with or without an SGLT2i), could provide an effective alternative to further up‐titration of basal insulin, while avoiding an increase in basal insulin dose, weight gain, and hypoglycaemia. Compared to SUSTAIN 11, we observed similar improvements in HbA1c (−1.4% in SUSTAIN OPTIMIZE vs. −1.5% in SUSTAIN 11), increased improvements in BW (−8.0 vs. −4.1 kg, respectively), and similar occurrences of hypoglycaemic episodes (4.9% vs. 19.3% for level 2 hypoglycaemia and 1.4% versus 0.5% for level 3 hypoglycaemia, respectively) in the respective semaglutide arms [27]. However, any difference in results should only be interpreted as numerical comparisons between trials, as there were differences in trial designs and target populations between the studies. By de‐escalating the basal insulin dose and focusing on GLP‐1 RA optimisation, this trial better reflects a strategy to curb basal‐insulin escalation rather than to test a standard basal‐bolus regimen. While this study made use of SMBG for insulin titration, the use of continuous glucose monitoring (CGM) data would serve to benefit the results presented here. CGM data can capture asymptomatic or nocturnal hypoglycaemia and time‐in‐range recordings, thereby providing a more nuanced picture of glycaemic control. However, this glycaemic control is not 1:1 with patient‐reported or SMBG‐detected episodes [28, 29]. Therefore, future studies should be devoted to including SMBG and CGM data to record glycaemic control and the occurrence of hypoglycaemic episodes. In summary, Sema+IGlarreduced was superior to IGlartitrated treatment in improving glycaemic control, reducing BW, reducing daily insulin dose, and improving DTSQc scores in participants with T2D and overweight. Semaglutide was well tolerated, with a safety profile similar to that of other GLP‐1 RAs, and was associated with lower rates of severe hypoglycaemia compared to IGlar treatment alone. Therefore, OW s.c. semaglutide 2.0 mg as add‐on to dose‐reduced IGlar provides an effective and safe treatment option for people with T2D compared to insulin titration alone. Author Contributions All authors were site investigators, except those employed by Novo Nordisk, and took part in the conduct of the trial and the data collection. The data were analysed by the statistical group for Novo Nordisk. H.W.R. served as a Principal Investigator. All the authors have reviewed and edited the manuscript and contributed to the discussion. All authors have read the report critically and approved the submitted version, and all authors take responsibility for the contents of the article. Funding This study was funded by Novo Nordisk. Conflicts of Interest H.W.R. has received grant support and fees for consultancy from Astra‐Zeneca, Boehringer Ingelheim, Janssen, Lilly, Novo Nordisk, and Sanofi. C.I. has provided advisory board services for Novo Nordisk, Roche Diabetes Care Italy, Abbott, Menarini, Ascensia, and Senseonics and has received speaker fees from Novo Nordisk, Roche Diabetes Care Italy, Abbott, Ascensia, Lilly, and Boehringer Ingelheim. J.L., P.P., and S.S. are all employees of Novo Nordisk. P.P. and S.S. are also shareholders of Novo Nordisk. K.M. has provided advisory board services for Novo Nordisk, Pharmaserve Lilly, Astra‐Zeneca, Boehringer Ingelheim, and has received speaker fees from Novo Nordisk, Pharmaserve Lilly, Boehringer Ingelheim, and Menarini. S.T.P. has provided advisory board services for Novo Nordisk, Lilly, Astra‐Zeneca, and Menarini, and has received speaker fees from Novo Nordisk, Lilly, and Menarini. A.B. has received research funding from Amgen, Endogenix, Gasherbrum Bio, VtV Therapeutics, Boehringer Ingelheim, Abbott Diabetes Care, AbbVie, Covance, Dexcom, Eli Lilly, Madrigal, Medtronic, NovoNordisk, MannKind, Carmot, Quintiles, Akero, 89 bio, Viking Therapeutics, Barbara Davis Center for Diabetes, Zydus, Kowa Pharmaceuticals America, Insulet, and Verdiva Bio, he has done advising/consulting for Boehringer Ingelheim, Novo Nordisk, and Verdiva Bio. Supporting information Table S1: Dose escalation and maintenance of once‐weekly semaglutide subcutaneous dose escalation and reduction of insulin glargine U100. Dose escalation plan for semaglutide and insulin glargine reduction for the trial. *Dose reduction of 10 U insulin for each escalation step was attempted in all participants regardless if they received less than 40 units/day at randomisation. OW, once‐weekly; s.c., subcutaneous; U, units. Table S2: Adjustment of insulin glargine U100 dose. Table outlining the adjustment of insulin glargine U100 dose during the trial. SMBG, self‐measured blood glucose. Table S3: Number of hypoglycaemic episodes by severity classification. The number of clinically significant hypoglycaemic episodes (level 2) (< 3.0 mmol/L) (54 mg/dL) and the number of severe hypoglycaemic episodes (level 3) at week 40 were analysed using negative binomial regression model with a log‐link function and the logarithm of time on‐treatment as offset. The model included randomised treatment, SGLT‐2 inhibitor use (Y/N) and region as fixed factors and baseline HbA1c as a covariate. Estimated rates were per 100 years of exposure time. BG, blood glucose; CI, confidence interval; IGlartitrated, dose‐titrated insulin glargine; SE, standard error of the mean; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGLT‐2, sodium‐glucose cotransporter‐2. Figure S1: Participant disposition. Overview of participant disposition. Figure S2: Relative body weight change at week 40. Exploratory efficacy endpoint. ****p < 0.0001. The responses were analysed using an ANCOVA with randomised treatment, SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline body weight value as a covariate. Before analysis, missing data were multiple imputed by imputing missing end of treatment data separately within groups defined by randomised treatment and treatment status at end of treatment, using an ANCOVA with SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline body weight value as a covariate fitted to the observed end of treatment values. ANCOVA, analysis of covariance; CI, confidence interval; ETD, estimated treatment difference; IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGLT2, sodium‐glucose cotransporter‐2. Figure S3: Proportion of participants achieving exploratory HbA1c target and body weight reduction targets. Exploratory efficacy endpoints are graphed for A–B, representing the proportion of participants achieving HbA1c < 6.5% and ≥ 5% or ≥ 10% weight reduction, respectively. IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine. Figure S4: Change from baseline to week 40 in daily insulin dose. The post‐hoc exploratory analyses for daily insulin dose at week 40 for absolute change in daily insulin dose. Mean ± SE are graphed. ****p < 0.0001. The responses were analysed using an ANCOVA with randomised treatment, SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline daily insulin dose value as a covariate. Before analysis, missing data were multiple imputed by imputing missing end of treatment data separately within groups defined by randomised treatment using an ANCOVA with SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline daily insulin dose value as a covariate fitted to the observed end of treatment values and the model assumed a different residual variance across the two treatment arms. ANCOVA, analysis of covariance; CI, confidence interval; ETD, estimated treatment difference; IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGLT2, sodium‐glucose cotransporter‐2. Figure S5: Participants achieving insulin dose targets at week 40. A. The predefined endpoint is graphed showing the proportion of participants that achieved an insulin dose reduction by ≥ 50% from baseline to end of treatment. B–C. The exploratory efficacy endpoints are graphed for the proportion of participants that reached ≤ 10 and 0 U, respectively. Data from in‐study with missing body weight were multiple imputed using observed data from participants within the same group defined by randomised treatment and same treatment status. After imputation, continuous data were dichotomised. IGlartitrated, dose‐titrated insulin glargine; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; U, units. Figure S6: DTSQc score at week 40. Mean values are graphed (SE would not be visible if included). ****p < 0.0001. The responses were analysed using an ANCOVA with randomised treatment, SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline DTSQs score as a covariate. Before analysis, missing data were multiple imputed by imputing missing end of treatment data separately within groups defined by randomised treatment using an ANCOVA with SGLT‐2 inhibitor use (YES/NO) and region as factors and baseline DTSQs score as a covariate fitted to the observed end of treatment values. ANCOVA, analysis of covariance; CI, confidence interval; DTSQc, diabetes treatment satisfaction questionnaire—change; ETD, estimated treatment difference; IGlartitrated, dose‐titrated insulin glargine; SE, standard error; Sema+IGlarreduced, semaglutide 2.0 mg as add‐on to dose‐reduced insulin glargine; SGLT2, sodium‐glucose cotransporter‐2.